{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:44:04Z","timestamp":1787741044427,"version":"build-2784847793"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.nmd.2025.105365","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T12:33:28Z","timestamp":1744893208000},"page":"105365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Aseptic meningoencephalitis during nusinersen therapy in a patient with type III spinal muscular atrophy: a case report"],"prefix":"10.1016","volume":"50","author":[{"given":"Lukasz","family":"Kolakowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Zschau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Bonzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"de Vere-Tyndall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Herwerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Neuwirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Schreiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-3156","authenticated-orcid":false,"given":"Veronika","family":"Kana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2025.105365_bib0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2025.105365_bib0002","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2025.105365_bib0003","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2025.105365_bib0004","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2025.105365_bib0005","first-page":"464","article-title":"Reader response: evidence in focus: nusinersen use in spinal muscular atrophy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the","volume":"93","author":"Takanashi","year":"2019","journal-title":"Am Acad Neurol Neurol"},{"key":"10.1016\/j.nmd.2025.105365_bib0006","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13023-021-01822-4","article-title":"The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): results from a US electronic health records study","volume":"16","author":"Viscidi","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2025.105365_bib0007","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.1002\/mus.27042","article-title":"Possible recurrent aseptic meningitis associated with nusinersen therapy","volume":"62","author":"Moshe-Lilie","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2025.105365_bib0008","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7453\/gahmj.2013.008","article-title":"The CARE Guidelines: consensus-based Clinical case reporting guideline development","volume":"2","author":"Gagnier","year":"2013","journal-title":"Glob Adv Health Med"},{"key":"10.1016\/j.nmd.2025.105365_bib0009","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1212\/WNL.94.15_supplement.2528","article-title":"SMA patient experienced aseptic meningitis with severe hypoglycorrhachia after Nusinersen infusion (2528)","volume":"94","author":"Janarious","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2025.105365_bib0010","unstructured":"EMAES. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spinraza."},{"key":"10.1016\/j.nmd.2025.105365_bib0011","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.neurol.2019.07.005","article-title":"Aseptic meningitis","volume":"175","author":"Tattevin","year":"2019","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.nmd.2025.105365_bib0014","unstructured":"FDA. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005."},{"key":"10.1016\/j.nmd.2025.105365_bib0015","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/waylivra-epar-product-information_en.pdf EMAEAISopc. 2022."},{"key":"10.1016\/j.nmd.2025.105365_bib0012","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209531Orig1s000SumR.pdf. 2016."},{"key":"10.1016\/j.nmd.2025.105365_bib0013","unstructured":"https:\/\/ec.europa.eu\/health\/documents\/community-register\/2019\/20190325144022\/anx_144022_en.pdf. 2019."}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625000926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625000926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T11:07:15Z","timestamp":1750849635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896625000926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":15,"alternative-id":["S0960896625000926"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2025.105365","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aseptic meningoencephalitis during nusinersen therapy in a patient with type III spinal muscular atrophy: a case report","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2025.105365","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105365"}}